US EditionPublished • loading... • Updated
Five-Day Azacitidine Best Among Shorter Hypomethylating Agent Regimens for Low-Risk MDS
Data from Taiho Oncology's studies show five-day azacitidine is most effective among shorter hypomethylating-agent regimens for low-risk myelodysplastic syndromes.
- At the ASH meeting in Orlando, Taiho Oncology, Inc. presented ASTX030-01 and ASTX727-03 data showing 5-day azacitidine produced superior survival with no new safety signals, announced Dec. 8, 2025.
- Researchers designed the trial to compare 3-day decitabine and 3- and 5-day azacitidine regimens in 249 patients, including transfusion-dependent and transfusion-independent groups.
- In the transfusion-independent cohort, investigators found 5-day azacitidine significantly improved EFS and yielded a higher overall response rate .
- Compared with best supportive care, 5-day azacitidine showed better EFS and OS , but randomization ended early and investigators urged a phase 3 trial.
- The results position azacitidine-cedazuridine to inform optimal doses and durations, while a key unresolved question is how 5-day azacitidine compares with luspatercept-aamt or imetelstat for future combination strategies and sequencing questions.
Insights by Ground AI
17 Articles
17 Articles
LoudounTimes.com+15 Reposted by 15 other sources
Taiho Oncology Presents Data on All-Oral Regimens Azacitidine and Cedazuridine, and Decitabine and Cedazuridine at the 2025 American Society of Hematology Annual Meeting and Exposition
Two oral presentations will highlight Phase 2 results from the ASTX030-01 trial of oral azacitidine and cedazuridine in patients with myelodysplastic syndromes, chronic myelomonocytic leukemia or acute myeloid leukemia and Phase 2 results from ASTX727-03 trial of low-dose oral decitabine…
Five-day azacitidine best among shorter hypomethylating agent regimens for low-risk MDS
ORLANDO — A decade-long investigation of shorter regimens of hypomethylating agents for low-risk myelodysplastic syndrome revealed a 5-day course of azacitidine significantly improved survival compared with 3-day azacitidine and decitabine.The results, presented at ASH Annual Meeting and Exposition, showed 5-day azacitidine improved EFS and OS with no early deaths or new safety signals.
Coverage Details
Total News Sources17
Leaning Left3Leaning Right2Center4Last UpdatedBias Distribution45% Center
Bias Distribution
- 45% of the sources are Center
45% Center
L 33%
C 45%
R 22%
Factuality
To view factuality data please Upgrade to Premium
